Ken Griffin’s Aimmune Therapeutics AIMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-63,000
| Closed | -$2.17M | – | 11887 |
|
|
2020
Q3 | $2.17M | Sell |
63,000
-700
| -1% | -$14.9K | ﹤0.01% | 4569 |
|
|
2020
Q2 | $1.06M | Buy |
63,700
+8,400
| +15% | +$143K | ﹤0.01% | 5725 |
|
|
2020
Q1 | $797K | Sell |
55,300
-107,000
| -66% | -$2.73M | ﹤0.01% | 5718 |
|
|
2019
Q4 | $5.43M | Buy |
162,300
+49,400
| +44% | +$1.38M | ﹤0.01% | 2975 |
|
|
2019
Q3 | $2.36M | Buy |
112,900
+25,200
| +29% | +$514K | ﹤0.01% | 4221 |
|
|
2019
Q2 | $1.83M | Buy |
87,700
+20,300
| +30% | +$418K | ﹤0.01% | 4670 |
|
|
2019
Q1 | $1.51M | Buy |
67,400
+9,900
| +17% | +$233K | ﹤0.01% | 4911 |
|
|
2018
Q4 | $1.38M | Buy |
57,500
+50,000
| +667% | +$1.29M | ﹤0.01% | 4777 |
|
|
2018
Q3 | $205K | Sell |
7,500
-9,100
| -55% | -$257K | ﹤0.01% | 8183 |
|
|
2018
Q2 | $446K | Buy |
16,600
+300
| +2% | +$9.18K | ﹤0.01% | 6560 |
|
|
2018
Q1 | $519K | Buy |
+16,300
| New | +$574K | ﹤0.01% | 5824 |
|
Ken Griffin's AIMT Position: Q4 2020 in Review
Ken Griffin sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 75,551 shares — an estimated $2.6M sold.
Ken Griffin first reported a position in AIMT in Q2 2016 and held it in 17 quarters. The position peaked at $13.9M in Q3 2017. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.
- Ken Griffin reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
- Ken Griffin sold 75,551 Aimmune Therapeutics shares in Q4 2020, an estimated $2.6M.
- Ken Griffin first reported a position in Aimmune Therapeutics in Q2 2016 and held it in 17 quarters.
- Ken Griffin's Aimmune Therapeutics position peaked at $13.9M in Q3 2017.
- 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.
Based on Citadel Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.